tradingkey.logo
tradingkey.logo
Search

Xtant Medical Holdings Inc

XTNT
Add to Watchlist
0.320USD
-0.007-2.14%
Close 09-18 16:00ET
45.59MMarket Cap
24.70P/E TTM
After-hours 18:30 (ET)0.320USD-0.005-1.54%

Xtant Medical Holdings Inc (XTNT) Revenue Performance

Updated: Jun 30, 2026

Last year, Xtant Medical Holdings Inc generated 72.89M USD for its biggest-performing segment, Orthobiologics. The United States made the largest contribution, accounting for 122.45M USD last year. For the latest quarter, Xtant Medical Holdings Inc reported the revenue of 17.36M USD for the period ending 2026-06-30, which came from the top-performing segment, Orthobiologics. United States contributed the highest revenue, at 22.46M USD.

By Business

Annual
Annual
Quarterly
Orthobiologics
Spinal implant
License revenue
Other revenue
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Orthobiologics
72.89M(54.43%)
66.42M(56.64%)
58.60M(64.19%)
47.14M(81.32%)
42.26M(76.47%)
39.31M(73.70%)
46.66M(72.14%)
48.98M(67.84%)
Spinal implant
42.31M(31.59%)
49.35M(42.08%)
32.70M(35.81%)
10.81M(18.66%)
12.89M(23.32%)
13.88M(26.02%)
17.87M(27.63%)
22.83M(31.62%)
License revenue
18.72M(13.98%)
1.50M(1.28%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Other revenue
--(--)
--(--)
--(--)
11.00K(0.02%)
117.00K(0.21%)
149.00K(0.28%)
147.00K(0.23%)
389.00K(0.54%)

By Region

Annual
Annual
Quarterly
United States
Rest of World
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
United States
122.45M(91.43%)
105.52M(89.98%)
85.86M(94.04%)
57.16M(98.61%)
54.57M(98.75%)
52.15M(97.77%)
62.38M(96.44%)
68.88M(95.40%)
79.74M(96.52%)
85.62M(95.13%)
56.75M(95.63%)
34.64M(98.05%)
32.49M(98.23%)
31.95M(96.87%)
29.57M(98.08%)
Rest of World
11.48M(8.57%)
11.75M(10.02%)
5.44M(5.96%)
807.00K(1.39%)
693.00K(1.25%)
1.19M(2.23%)
2.31M(3.56%)
3.32M(4.60%)
2.87M(3.48%)
4.38M(4.87%)
2.60M(4.37%)
688.24K(1.95%)
584.59K(1.77%)
1.03M(3.13%)
578.04K(1.92%)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.